Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)

Trial Profile

Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Pegargiminase (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms ATOMIC
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jan 2017 Planned End Date changed from 1 Dec 2020 to 1 Jun 2018.
    • 03 Jan 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top